Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
Type:
Grant
Filed:
June 28, 2019
Date of Patent:
April 12, 2022
Assignees:
Les Laboratories Servier, Institut National de Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifiaue (CNRS)
Abstract: The present disclosure provides methods of treating liver cancer and preventing liver cancer recurrence with anti-progastrin antibodies, methods of monitoring treatment efficacy of anti-progastrin therapy for liver cancer, and compositions useful therefore.
Type:
Grant
Filed:
July 22, 2011
Date of Patent:
January 14, 2020
Assignees:
Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Les Laboratories Servier
Abstract: Process for the optical resolution of the compound of formula (I): by chiral chromatography. Application in the synthesis of ivabradine, of its addition salts with a pharmaceutically acceptable acid and of their hydrates.
Type:
Grant
Filed:
March 26, 2013
Date of Patent:
January 6, 2015
Assignee:
Les Laboratories Servier
Inventors:
Jean-Michel Lerestif, Jean-Pierre Lecouve, Daniel Dron, Eric Gojon, Maryse Phan
Abstract: The present disclosure is directed to methods of treating and preventing breast cancer or recurrence of breast cancer with compositions comprising anti-progastrin antibodies.
Type:
Grant
Filed:
January 4, 2011
Date of Patent:
December 2, 2014
Assignees:
Les Laboratories Servier, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
Abstract: Process for the optical resolution of the compound of formula (I): by chiral chromatography. Application in the synthesis of ivabradine, of its addition salts with a pharmaceutically acceptable acid and of their hydrates.
Type:
Grant
Filed:
March 26, 2013
Date of Patent:
July 15, 2014
Assignee:
Les Laboratories Servier
Inventors:
Jean-Michel Lerestif, Jean-Pierre Lecouve, Daniel Dron, Eric Gojon, Maryse Phan
Abstract: Polymerized micelles comprising polymerized amphiphilic molecules obtained starting from amphiphilic molecules having one or two lipid chains each comprising one or two polymerizable moieties and linked to a polar head.
Type:
Grant
Filed:
April 28, 2009
Date of Patent:
March 4, 2014
Assignees:
Les Laboratories Servier, Commissariat a l'Energie Atomique
Inventors:
Julien Ogier, Eric Doris, François Lefoulon, Thomas Arnauld
Abstract: The invention provides a new crystalline form of agomelatine, preparation and use thereof. The X-ray powder diffraction diagram of the agomelatine crystalline form shows main peaks at the diffraction angles 2? 11.13°, 11.82°, 17.49°, 18.29°, 19.48°, 19.72°, 20.50°, 21.76°, 22.54°, 22.97°, 24.56°, 25.36°, 27.16° and 31.93°. Said new crystalline form is characterized by high purity, stability and good reproducibility, and thus is advantageous for the pharmaceutical formulation. In addition, the stability and solubility of said crystalline form are also superior over the several existing crystalline forms.
Abstract: The present invention relates to a complex of agomelatine and to preparation thereof. The hydrogen halide complex of agomelatine obtained through the present method is more soluble, more stable, and of higher purity than agomelatine itself, making it more suitable to be used in pharmaceutical preparation. Using this method, product of high purity can be obtained through a simple process, without having to incur further complicated steps.
Abstract: Compounds of formula (I): wherein: R1 and R2, which may be the same or different, each represent a hydrogen or halogen atom or an alkyl, alkoxy, alkylthio, acyl, alkoxycarbonyl, carboxy, hydroxy, hydroxyalkyl, cyano, nitro, amino, substituted or unsubstituted aminocarbonyl, aminosulphonyl, alkylsulphonylaminoalkyl, N-hydroxy-carboximidamide or benzyloxy group, R3 represents a hydrogen atom or an alkyl, cycloalkyl or cycloalkylalkyl group, R4 represents a hydrogen atom or a substituted or unsubstituted alkyl group Medicinal products containing the same which are useful in treating or preventing conditions treatable by an AMPA receptor modulator and/or an NMDA receptor antagonist.
Type:
Grant
Filed:
March 19, 2010
Date of Patent:
August 7, 2012
Assignee:
Les Laboratories Servier
Inventors:
Alexis Cordi, Patrice Desos, Pierre Lestage, Laurence Danober
Abstract: Compounds of formula (I): wherein: R1 represents an alkyl, cycloalkyl or cycloalkylalkyl group, R2 represents a linear or branched (C1-C6)alkyl group, and n represents from 1 to 6. Medicaments.
Type:
Grant
Filed:
October 17, 2007
Date of Patent:
August 23, 2011
Assignee:
Les Laboratories Servier
Inventors:
Pascal Marchand, Vincent Babonneau, Sylvie Piessard, Muriel Duflos, Jean Albert Boutin, Valérie Audinot, Philippe Delagrange, Daniel-Henri Caignard
Abstract: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, on its own or in association, in obtaining medicaments intended for the treatment of bipolar disorders, especially bipolar disorders of types I and II, and more especially bipolar disorders of type I.
Abstract: The invention relates to a method of screening and identifying modulators of the protein interaction between new peptides and anti-apoptotic members of the Bcl-2 protein family. The modulators identified on the basis of this method are administered to patients with cancer in order to bring about apoptotic-type and/or autophagic-type programmed cell death in those patients.
Type:
Grant
Filed:
January 31, 2006
Date of Patent:
April 19, 2011
Assignees:
Les Laboratories Servier, Hybrigenics
Inventors:
Olivier Geneste, John Hickman, Jean-Christophe Rain
Abstract: A ?-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.
Abstract: Compound of formula (I): wherein: represents 1-oxidopyridyl substituted by the remainder of the molecule in any one of the positions 2, 3 and 4, m and n, which may be identical or different, each represent an integer of from 1 to 3, R1 represents hydrogen or alkyl, R2 and R3, which may be identical or different, each represent an atom or group selected from hydrogen, halogen, alkyl, hydroxy, acyloxy and alkoxy, or, together with the carbon atom carrying them, form a cycloalkane having from 3 to 6 carbon atoms, R4 and R5 each represent hydrogen, or are adjacent and, together with the carbon atoms carrying them, form a benzo ring, Ar represents aryl or heteroaryl. Medicinal products containing the same which are useful as thrombin inhibitors.
Type:
Grant
Filed:
March 14, 2005
Date of Patent:
March 3, 2009
Assignee:
Les Laboratories Servier
Inventors:
Guillaume De Nanteuil, Philippe Gloanec, Jean-Gilles Parmentier, Alain Benoist, Alain Rupin, Marie-Odile Vallez, Tony Verbeuren